Thogus Products Company v. Bleep, LLC

District Court, N.D. Ohio·Decided June 4, 2021·No. 1:20-cv-01887·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO

THOGUS PRODUCTS COMPANY, CASE NO. 1:20-cv-1887

Plaintiff, -vs- JUDGE PAMELA A. BARKER

BLEEP, LLC, MEMORANDUM OF OPINION AND Defendant. ORDER

Currently pending is Plaintiff Thogus Products Company’s Motion to Dismiss Count VI of Defendant Bleep, LLC’s Counterclaim. (Doc. No. 21.) Defendant Bleep, LLC filed a Brief in Opposition on February 19, 2021, to which Plaintiff replied on February 26, 2021. (Doc. Nos. 31, 35.) For the following reasons, Plaintiff’s Motion to Dismiss is granted. I. Background Defendant Bleep, LLC (hereinafter “Bleep”) develops and sells certain medical devices for the treatment of sleep apnea, including the DreamWay and DreamPort products. (Doc. No. 12, ¶ 8.) Both products are designed to work with continuous positive airway pressure (“CPAP”) machines and are finished medical devices under applicable federal law and regulations promulgated by the United States Food & Drug Administration (“FDA”). (Id. at ¶ 8, 11.) While researching potential manufacturers for the DreamWay and DreamPort, Bleep learned that Plaintiff Thogus Products Company (“Thogus”) was interested in becoming a contract manufacturer of finished medical devices. (Id. at ¶ 12.) Although Thogus only manufactured medical device components at the time the two companies entered negotiations, Thogus expressed a desire to Bleep in becoming a finished medical devices manufacturer. (Id. at ¶ 13.) Between late 2017 and early 2018, Thogus and Bleep entered into negotiations for an agreement whereby Thogus would manufacture Bleep’s DreamWay and DreamPort products. (Id. at ¶¶ 12-22.) Bleep claims that, during these negotiations, Thogus represented that it either was already in compliance with, or would achieve compliance with, manufacturing and regulatory compliance standards for a “finished medical device” manufacturer under the FDA. (Id. at ¶¶ 16-22.) In addition, Bleep alleges that Thogus represented that it would be able to satisfy Bleep’s specifications and

quality standards for the DreamWay and DreamPort products. (Id.) Bleep alleges that, in entering a manufacturing contract with Thogus, it relied on what it purports were Thogus’s false representations and assurances with respect to Thogus’s ability and intent to establish manufacturing operations that complied with medical device regulations. (Id. at ¶ 25.) On March 2, 2018, Bleep and Thogus entered into a Manufacturing Supply Agreement (“MSA”) for the manufacture of the DreamWay and DreamPort products. (Id. at ¶¶ 28-29.) Of particular relevance herein, Section 17.15 of MSA contains the following choice of law provision: 17.15 Governing Law. This Agreement, including all exhibits, schedules, attachments and appendices attached hereto and thereto, are governed by, and construed in accordance with, the Laws of the State of Ohio, United States of America, without regard to the conflict of laws provisions thereof.

(Doc. No. 12-2, PageID# 317.) On December 29, 2020, Bleep filed its Answer to Thogus’s Complaint, as well as its Verified Counterclaims. (Doc. No. 12.) In Count VI of its Counterclaims, Bleep asserts that Thogus’s conduct constituted unfair or deceptive trade practices in violation of North Carolina’s Unfair and Deceptive Trade Practices Act (“NC UDTPA”). (Id. at ¶¶ 194-99.) Thogus moves to dismiss Count VI, the NC UDTPA claim, only. (Doc. No. 21.) 2 II. Standard of Review Thogus moves to dismiss Bleep’s Count VI for failure to state a claim under Fed. R. Civ. P. 12(b)(6). Under Fed. R. Civ. P. 12(b)(6), the Court accepts the plaintiff’s factual allegations as true and construes the Complaint in the light most favorable to the plaintiff. See Gunasekara v. Irwin, 551 F.3d 461, 466 (6th Cir. 2009). In order to survive a motion to dismiss under this Rule, “a complaint must contain (1) ‘enough facts to state a claim to relief that is plausible,’ (2) more than ‘a

formulaic recitation of a cause of action’s elements,’ and (3) allegations that suggest a ‘right to relief above a speculative level.’” Tackett v. M & G Polymers, USA, LLC, 561 F.3d 478, 488 (6th Cir. 2009) (quoting in part Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555-56, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)). The measure of a Rule 12(b)(6) challenge—whether the Complaint raises a right to relief above the speculative level—“does not ‘require heightened fact pleading of specifics, but only enough facts to state a claim to relief that is plausible on its face.’” Bassett v. National Collegiate Athletic Ass’n., 528 F.3d 426, 430 (6th Cir. 2008) (quoting in part Twombly, 550 U.S. at 555-56, 127 S.Ct. 1955). “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v.

Iqbal, 556 U.S. 662, 678, 129 S.Ct. 1937, 173 L.Ed.2d 868 (2009). Deciding whether a complaint states a claim for relief that is plausible is a “context-specific task that requires the reviewing court to draw on its judicial experience and common sense.” Id. at 679. Consequently, examination of a complaint for a plausible claim for relief is undertaken in conjunction with the “well-established principle that ‘Federal Rule of Civil Procedure 8(a)(2) requires only a short and plain statement of the claim showing that the pleader is entitled to relief.’ Specific

3 facts are not necessary; the statement need only ‘give the defendant fair notice of what the . . . claim is and the grounds upon which it rests.’” Gunasekera, 551 F.3d at 466 (quoting in part Erickson v. Pardus, 551 U.S. 89, 127 S.Ct. 2197, 2200, 167 L.Ed.2d 1081 (2007)) (quoting Twombly, 127 S.Ct. at 1964). Nonetheless, while “Rule 8 marks a notable and generous departure from the hyper- technical, code-pleading regime of a prior era . . . it does not unlock the doors of discovery for a plaintiff armed with nothing more than conclusions.” Iqbal, 556 U.S. at 679, 129 S.Ct. 1937.

III. Analysis Thogus asserts that Bleep’s Count VI should be dismissed because the MSA’s clear and unambiguous choice of law provision precludes Bleep from seeking relief under North Carolina law. (Doc. No. 21-2, PageID# 421-22.) Bleep contends that North Carolina law applies because the MSA’s choice of law provision governs only contract claims, not tort claims like Bleep’s unfair trade practices claim in Count VI. (Doc. No. 31, PageID# 505-06.) For the following reasons, the Court concludes that Ohio law governs and, therefore, Bleep’s Count VI should be dismissed. A court exercising diversity jurisdiction must apply the choice-of-law rules of the forum state. Glenway Indus., Inc. v. Wheelabrator-Frye, Inc., 686 F.2d 415, 417 (6th Cir. 1982). Therefore, Ohio’s choice of law rules apply. The Ohio Supreme Court has adopted the Restatement (Second)

Free access — add to your briefcase to read the full text and ask questions with AI

Thogus Products Company v. Bleep, LLC, (N.D. Ohio 2021).

Thogus Products Company v. Bleep, LLC (Thogus Products Company v. Bleep, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Erickson v. Pardus
551 U.S. 89 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Glenway Industries, Inc. v. Wheelabrator-Frye, Inc.
686 F.2d 415 (Sixth Circuit, 1982)
Bassett v. National Collegiate Athletic Ass'n
528 F.3d 426 (Sixth Circuit, 2008)
Tackett v. M & G POLYMERS, USA, LLC
561 F.3d 478 (Sixth Circuit, 2009)
Gunasekera v. Irwin
551 F.3d 461 (Sixth Circuit, 2009)
Baumgardner v. Bimbo Food Bakeries Distribution, Inc.
697 F. Supp. 2d 801 (N.D. Ohio, 2010)
Banek Inc. v. Yogurt Ventures U.S.A., Inc.
6 F.3d 357 (Sixth Circuit, 1993)